Centra Medyczne Medyceusz Sp. z o.o.

Lodz 10 trials 1 recruiting

10 Registered trials

1 Currently recruiting

Organisation

Centra Medyczne Medyceusz Sp. z o.o.

Location

Lodz, Poland

Identifier

ORG-100042822

Address

Ul. Bazarowa 9, 91-053, Poland

Departments

Centra Medyczne Medyceusz
Centra Medyczne Medyceusz - Bazarowa
n/a
NA
Obstetrics and Gynecology
Site name: Centra Medyczne Medyceusz- Bazarowa

Clinical trials at this site (10)

Search interface

Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
A multicenter, open-label, controlled study to investigate the effect of either LF111 or Drospirenone chewable tablets on bone mineral densi… Ended

2024-512347-23-00 Oral contraception 6 2022-08-22
A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with … Ended

2022-501310-57-00 Endometriosis related pain 4 2024-02-05
Study to investigate the efficacy of chaste tree (Vitex agnus-castus BNO 1095 (20 mg)) in women with cramping pain in the lower abdomen occu… Ended

2023-503688-41-00 Primary Dysmenorrhea 5 2023-11-28
A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any kno… Ended

2022-501885-24-00 Contrast enhancement in magnetic resonance imaging for 5 2023-09-20
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 Severe hypertryglyceridemia 5 2023-05-17
A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus Ended

2022-500445-24-00 Moderately to Severely Active Systemic Lupus Erythemato 5 2022-11-30
Efficacy and safety of the proposed biosimilar PERT-IJS versus EU-Perjeta® along with trastuzumab and chemotherapy (carboplatin and docetaxe… Ended

2023-506163-34-00 Hormone Receptor Negative (HR-ve) Human Epidermal Growt 5